Literature DB >> 17884266

Cognitive functioning related to quality of life in schizophrenia.

Mié Matsui1, Tomiki Sumiyoshi, Hirofumi Arai, Yuko Higuchi, Masayoshi Kurachi.   

Abstract

The present study compared the cognitive function of patients with schizophrenia to that of healthy subjects, and investigated the relationships between cognitive function and quality of life (QOL). Participants consisted of 53 patients meeting DSM-IV criteria for schizophrenia and 31 normal controls. All participants completed a neuropsychological test battery assessing executive function, verbal memory, and social knowledge. QOL was rated using the Schizophrenia Quality of Life Scale. Patients with schizophrenia showed lower performance across various cognitive measures of memory, including the Sentence Memory Test, the Verbal Learning Test, and the Script Test, as well as the Rule Shift Cards Test of executive function. Multiple regression analyses were used to evaluate the neuropsychological measures and clinical symptoms to predict QOL. The QOL total score, the social initiative score or the empathy score were significantly predicted by the Script or/and the Sentence Memory. Neuropsychological functioning was unrelated to most QOL scores in the presence of clinical symptoms, while ability of empathy in the QOL was predicted by performance of the Sentence Memory Test. These results demonstrated patients with schizophrenia have deficits in executive function, memory and learning, and social knowledge, and that social knowledge and memory are related to QOL. Thus, in patients with schizophrenia, deficits in social knowledge appear to be associated with current QOL in general, and specifically with the capacity for empathy and social initiative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884266     DOI: 10.1016/j.pnpbp.2007.08.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation.

Authors:  Arielle W Tolman; Matthew M Kurtz
Journal:  Schizophr Bull       Date:  2010-07-11       Impact factor: 9.306

Review 2.  European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Stefano Barlati; Giulia Maria Giordano; Gabriele Nibbio; Merete Nordentoft; Til Wykes; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

3.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Authors:  Brian Villumsen Broberg; Birte Yding Glenthøj; Rebecca Dias; Dorrit Bjerg Larsen; Christina Kurre Olsen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

4.  Clinical correlates of parametric digit-symbol substitution test in schizophrenia.

Authors:  Anekal C Amaresha; Vijay Danivas; Venkataram Shivakumar; Sri Mahavir Agarwal; Sunil V Kalmady; Janardhanan C Narayanaswamy; Ganesan Venkatasubramanian
Journal:  Asian J Psychiatr       Date:  2014-05-09

5.  Association between sleep quality and domains of quality of life amongst patients with first episode psychosis.

Authors:  Wei Jie Ong; Xiao Wei Tan; Shazana Shahwan; Pratika Satghare; Laxman Cetty; Boon Tat Ng; Charmaine Tang; Swapna Verma; Siow Ann Chong; Mythily Subramaniam
Journal:  Health Qual Life Outcomes       Date:  2020-04-29       Impact factor: 3.186

6.  Cognitive Deterioration and Quality of Life in Patients with Schizophrenia: A Single Institution Experience.

Authors:  Jorge Avila; Larissa Villacrés; Diego Rosado; Evelyn Loor
Journal:  Cureus       Date:  2020-01-25

7.  Functional and anatomical connectivity abnormalities in cognitive division of anterior cingulate cortex in schizophrenia.

Authors:  Hao Yan; Lin Tian; Jun Yan; Wei Sun; Qi Liu; Yan-Bo Zhang; Xin-Ming Li; Yu-Feng Zang; Dai Zhang
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

8.  Profile of blonanserin for the treatment of schizophrenia.

Authors:  Tomomi Tenjin; Seiya Miyamoto; Yuriko Ninomiya; Rei Kitajima; Shin Ogino; Nobumi Miyake; Noboru Yamaguchi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-29       Impact factor: 2.570

9.  Comparison of Visuospatial and Verbal Abilities in First Psychotic Episode of Schizophrenia Spectrum Disorder: Impact on Global Functioning and Quality of Life.

Authors:  Mabel Rodriguez; Filip Spaniel; Lucie Konradova; Katerina Sedlakova; Karolina Dvorska; Jitka Prajsova; Zuzana Kratochvilova; David Levcik; Kamil Vlcek; Iveta Fajnerova
Journal:  Front Behav Neurosci       Date:  2015-12-18       Impact factor: 3.558

10.  Olanzapine Reverses MK-801-Induced Cognitive Deficits and Region-Specific Alterations of NMDA Receptor Subunits.

Authors:  Xiao Liu; Jitao Li; Chunmei Guo; Hongli Wang; Yaxin Sun; Han Wang; Yun-Ai Su; Keqing Li; Tianmei Si
Journal:  Front Behav Neurosci       Date:  2018-01-09       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.